Imvax, Inc., a developer of immunotherapy for Glioblastoma (GBM) and other cancers, has appointed Sean Hemingway as Chief Operating Officer. Hemingway will lead the expansion of Imvax’s new manufacturing facility at The Curtis and support IT and facilities management functions. He will also oversee the manufacturing and supply organization, while building out Imvax’s cell therapy platform. “Sean brings invaluable knowledge of project management, manufacturing operati...